Pfizer Inc. has terminated its global collaboration and license agreement with Sangamo Therapeutics for giroctocogene fitelparvovec, an investigational gene therapy for hemophilia A. As a result, Sangamo Therapeutics will regain full development and commercialization rights to the program, effective April 21, 2025.
Pfizer indicated that its decision not to proceed with Biologics License Application (BLA) and Marketing Authorisation Application (MAA) submissions, or to pursue commercialization of giroctocogene fitelparvovec, despite positive Phase 3 AFFINE trial results announced in July 2024. The AFFINE trial had met its primary and key secondary objectives.
This termination represents a pipeline setback for Pfizer in the gene therapy space and a shift in its strategic focus for hemophilia A. Sangamo Therapeutics plans to explore all options to advance the program, including seeking a new collaboration partner, given the compelling clinical trial data.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.